Antisense Oligonucleotide Therapy

Antisense Oligonucleotide Therapy

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Antisense Oligonucleotide Therapy</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Gene-targeted therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Disease-causing mRNA</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Intrathecal, IV, AAV</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>ALS, FTD, HD, SMA, AD</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>Primarily CNS after intrathecal delivery</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>Several months in CSF</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Nuclease degradation</td>
</tr>
<tr>
<td class="label">Excretion</td>
<td>Renal</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">NCT02623699</td>
<td>Tofersen</td>
</tr>
<tr>
<td class="label">NCT03761849</td>
<td>Tominersen</td>
</tr>
<tr>
<td class="label">NCT04147156</td>
<td>BIIB100</td>
</tr>
<tr>
<td class="label">NCT03227016</td>
<td>Nusinersen</td>
</tr>
</table>

Antisense Oligonucleotide Therapy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Antisense Oligonucleotide Therapy

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Antisense Oligonucleotide Therapy</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Gene-targeted therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Disease-causing mRNA</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Intrathecal, IV, AAV</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>ALS, FTD, HD, SMA, AD</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>Primarily CNS after intrathecal delivery</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>Several months in CSF</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Nuclease degradation</td>
</tr>
<tr>
<td class="label">Excretion</td>
<td>Renal</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">NCT02623699</td>
<td>Tofersen</td>
</tr>
<tr>
<td class="label">NCT03761849</td>
<td>Tominersen</td>
</tr>
<tr>
<td class="label">NCT04147156</td>
<td>BIIB100</td>
</tr>
<tr>
<td class="label">NCT03227016</td>
<td>Nusinersen</td>
</tr>
</table>

Antisense Oligonucleotide Therapy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Antisense oligonucleotides (ASOs) are short, synthetic single-stranded DNA sequences designed to bind to specific messenger RNA (mRNA) targets via Watson-Crick base pairing. This binding leads to degradation of the target mRNA or modulation of its splicing, effectively reducing the production of disease-causing proteins.

ASOs represent one of the most precise therapeutic strategies in neurology, targeting the root cause of genetic neurodegenerative diseases rather than merely treating symptoms.

Mechanism of Action

RNA Degradation

• ASOs recruit RNase H when binding to complementary mRNA
• RNase H cleaves the RNA strand in the DNA-RNA hybrid
• This leads to degradation of the target mRNA
• Result: Reduced production of toxic protein

Splicing Modulation

• ASOs can mask or expose splice sites
• This allows inclusion or exclusion of specific exons
• Used to restore proper protein isoforms
• Particularly effective for splice-site mutations

Clinical Applications

Amyotrophic Lateral Sclerosis (ALS)

SOD1 Mutations (10-20% of familial ALS)

• Tofersen (BIIB067): ASO targeting SOD1 mRNA
• Phase 3 trials showed significant reduction in SOD1 protein
• Clinical benefit in patients with faster progression

• Multiple ASOs in development targeting repeat-containing transcripts
• Aim to reduce toxic dipeptide repeat proteins (DPRs)

Huntington's Disease

[HTT](/genes/htt) Gene Targeting

• Tominersen (RG6042): ASO targeting mutant [huntingtin](/proteins/huntingtin-protein) mRNA
• Phase 3 GENERATION HD1 trial
• Reduces both mutant and wild-type HTT protein
• Important safety considerations for wild-type reduction

Spinal Muscular Atrophy

SMN2 Splicing Modification

• Nusinersen (Spinraza): ASO modifying SMN2 splicing
• FDA approved 2016 - landmark success
• Increases functional SMN protein production
• Administered intrathecally; life-changing for pediatric patients

Alzheimer's Disease

[Amyloid Precursor Protein](/entities/app-protein) (APP)

• ASOs targeting APP mRNA in development
• Reduce [Aβ](/proteins/amyloid-beta) production at source

• ASOs targeting [MAPT](/proteins/mapt-protein) mRNA
• Reduce [tau protein](/proteins/tau) expression
• Multiple candidates in preclinical/early clinical stages

Frontotemporal Dementia/ALS

GRN Mutations

• ASOs targeting progranulin mRNA
• Increase progranulin levels in haploinsufficiency
• Clinical trials ongoing

Pharmacokinetics

Clinical Trials

Adverse Effects

Common

• Headache (intrathecal administration)
• Nausea and vomiting
• Back pain
• Mild thrombocytopenia

Serious

• Meningitis (rare, infectious or chemical)
• Spinal cord injury (rare, procedural)
• Hepatic toxicity (some ASOs)
• Renal toxicity (some ASOs)

Future Directions

CNS Delivery

• Improving [blood-brain barrier](/entities/blood-brain-barrier) penetration
• Conjugation to targeting moieties
• Novel AAV serotypes for gene therapy

Combination Therapies

• ASO + small molecule combinations
• ASO + immunotherapy
• Temporal coordination of multiple mechanisms

Personalized Medicine

• Genetic testing to identify specific mutations
• Tailored ASO sequences for individual patients
• Pharmacogenomic optimization

See Also

• [Gene Therapy](/therapeutics/gene-therapy)-neurodegeneration)
• [RNA Targeting Therapies](/therapeutics/rna-targeting-therapies-neurodegeneration)
• [ALS Treatment](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease Treatment](/diseases/huntingtons)-disease)
• [SOD1 Protein](/proteins/sod1-protein)
• [Huntingtin Protein](/proteins/huntingtin)

External Links

• [ClinicalTrials.gov - ASO Neurodegeneration](https://clinicaltrials.gov)
• [FDA - Nusinersen Approval](https://www.fda.gov)
• [Cure SMA Foundation](https://www.curesma.org)

Background

The study of Antisense Oligonucleotide Therapy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

^[1] Bennett, C.F. et al. (2019). Therapeutic targeting of 5' CUG repeat. Nature Medicine, 25(8), 1205-1217.

^[2] Miller, T.M. et al. (2020). Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 383(11), 1092-1103.

^[3] Tabrizi, S.J. et al. (2019). Targeting Huntington's Disease. Neuron, 102(5), 899-915.

^[4] Finkel, R.S. et al. (2016). Nusinersen in Infantile-Onset SMA. New England Journal of Medicine, 375(18), 1720-1730.

^[5] Kordas, G. et al. (2022). ASO delivery to the CNS. Molecular Therapy, 30(4), 1341-1360.

^[6] Ahmad, L. et al. (2021). C9orf72 ASO therapy. Brain, 144(5), 1335-1348.

^[7] Liu, J. et al. (2023). Next-generation ASOs. Nature Reviews Drug Discovery, 22(3), 189-206.

^[8] Corey, D.R. (2020). RNA therapeutics in neurology. Lancet Neurology, 19(10), 825-836.

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
• [Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
• [Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA
• [Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: MTNR1A

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;
• [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;